Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676673 | 1.00 | PYCR1 (0.49) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL27755414 | 0.82 | PYCR1 (0.46) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL2867783 | 0.81 | CA1 (0.38) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL30169578 | 0.81 | PYCR1 (0.49) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL12164465 | 0.81 | PYCR1 (0.49) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL29418547 | 0.79 | PYCR1 (0.47) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL607749 | 0.79 | PYCR1 (0.47) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL30352488 | 0.79 | PYCR1 (0.47) | PYCR1ALDH1A1MAPK1SIGMAR1KDM5A | |
| SCHEMBL8587112 | 0.79 | PYCR1 (0.47) | PYCR1CA1CA2ALDH1A1MAPK1 | |
| SCHEMBL375783 | 0.79 | PYCR1 (0.47) | PYCR1CA1CA2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-28 | — | — | US | disclosed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2025075089-A1 | BIARYL COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE | 住友化学株式会社 | 2025-04-10 | — | — | WO | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4429770-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
| EP-0594019-B1 | 1-Biphenylmethyl-pyridone derivatives, their preparation and their use as angiotensin II antagonistes | BAYER AG (DE) | 2000-02-23 | — | — | EP | disclosed |
| US-5863930-A | ATHEROSCLEROSIS TREATMENT FORMED BY REACTION OF PYRIDONES WITH BIPHENYLMETHYL HALOGEN | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5596006-A | ANTIHYPERTENSIVE, ANTIATHEROSCLEROTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-01-21 | — | — | US | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0328643-B1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO CORP (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0594019-A1 | Trisubstituted biphenyl as angiotensin II antagonistes | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
| US-5043142-A | Measuring peroxide-active substances | TERUMO KABUSHIKI KAISHA (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0328643-A1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO KABUSHIKI KAISHA (JP) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | ESRRA, FSHR, GPER1 | PYCR1 532/4885CA1 537/4885CA2 757/4885 |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | PYCR1 1671/4885CA1 4621/4885CA2 4243/4885 |
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | PYCR1 2261/4885CA1 2198/4885CA2 358/4885 |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | PYCR1 4194/4885CA1 4874/4885CA2 4773/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | PYCR1 4526/4885CA1 4677/4885CA2 2407/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | PYCR1 1507/4885CA1 3414/4885CA2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.